Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase III Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

The Phase III clinical trial of CAN-2409 in intermediate-to-high-risk, localized prostate cancer met its primary endpoint, by demonstrating statistically significant improvement in disease-free survival in patients who received CAN-2409 plus prodrug combined with standard of care compared to standard of care alone.